Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference

in response to

Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference

narmac

posted on Jun 22, 2022 10:40AM

narmac,

Thats exactly what i was thinking since several BP have clincal collaberation deals with Zenith for several years now so if they like what they see which looks very promising the next step would be a major partnership deal or staged buyout , this could be 1 or 2 or 3 or 4years from now, anyones guess but BP have the money...

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply